Omega Therapeutics, Inc.
OMGADelisted Mar 20, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850838
Omega Therapeutics, Inc. was delisted on Mar 20, 2025; its insiders filed their last Form 4 on Dec 5, 2024; 53 institutions reported holding it in 13F filings for Q4 2024, worth $35.3M in total; no superinvestor held it.
Q4 2023 vs. Q3 2023
How the institutions holding Omega Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 58 | 1 | 63 | +6 |
| Shares | 50.9M | 1.06M | 50.2M | +399.2K (+0.8%) |
| Value | $109.4M | $2.27M | $151.2M | +$44.1M (+41.2%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Omega Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Blue Owl Capital Holdings LP | 1,055,882 | $3.18M | 0.76% |
| Zacks Investment Management | 306,426 | $922.3K | 0.01% |
| Jacobs Levy Equity Management, Inc | 298,281 | $897.8K | 0.00% |
| Amundi | 26,347 | $110.9K | 0.00% |
| Jane Street Group, LLC | 31,261 | $94.1K | 0.00% |
| Two Sigma Investments, LP | 30,133 | $90.7K | 0.00% |
| Renaissance Technologies LLC | 20,400 | $61.0K | 0.00% |
| Murphy Pohlad Asset Management LLC | 16,500 | $49.7K | 0.02% |
| Etfidea, LLC | 13,050 | $39.3K | 0.01% |
| McGlone Suttner Wealth Management, Inc. | 6,591 | $19.8K | 0.00% |
| Raleigh Capital Management Inc. | 2,096 | $6.31K | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 1,164 | $3.50K | 0.00% |
| Advisor Group Holdings, Inc. | 852 | $2.56K | 0.00% |
| Advisory Services Network, LLC | 638 | $1.92K | 0.00% |
| Allworth Financial LP | 268 | $807 | 0.00% |
| Huntington National Bank | 1 | $3 | 0.00% |
Sold out (10)
Institutions that held Omega Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Knoll Capital Management, LLC | 173,010 | $372.0K |
| Oracle Investment Management Inc | 50,000 | $107.5K |
| Citadel Advisors LLC | 25,906 | $55.7K |
| Dimensional Fund Advisors LP | 19,505 | $41.9K |
| Mirae Asset Global Investments Co., Ltd. | 15,047 | $32.4K |
| Allspring Global Investments Holdings, LLC | 2,577 | $5.54K |
| China Universal Asset Management Co., Ltd. | 1,414 | $3.04K |
| Lazard Asset Management LLC | 1,797 | $3.00K |
| Nisa Investment Advisors, LLC | 31 | $67 |
| Daiwa Securities Group Inc. | 139 | $0 |
Not filed for Q4 2023 yet (1)
Institutions that held Omega Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| CHI Advisors LLC | 1,055,882 | $2.27M |